Axicabtagene ciloleucel

Can you review, for those of us who don't treat follicular lymphoma, what the options for third-line disease looked like prior to the development of chimeric antigen T-cell receptor therapy in this setting?

This trial was coming up along with the other constructs, TSA cell and AXA cell.

Third line and beyond, follicular lymphoma was a very difficult disease to treat.

And in fact, we would continue to talk about allogeneic transplant in this population because historically they had received chemoimmunotherapy, novel agents, and we now have a much longer list in terms of therapeutic options, including CD19 directed therapy, bispecific therapy, which was not available at that time.

It closed its $7.8 billion R-Kelix acquisition in April, which gave it full control, and ended future profit-sharing, milestone, and royalty obligations.

Its kite unit already markets the CAR-T therapies Yescarta and Tacardus in other blood cancers, so a Nito cell would add myeloma to that business.

Later phase development is continuing, and the application is already under FDA review.

which is the right frame for this paper.